HOME >> MEDICINE >> NEWS
Temple University Hospital investigates treatment for cervical dysplasia

PHILADELPHIA -- Temple University Hospital's Center For Women's Health is participating in a national study to determine the safety and effectiveness of an investigational treatment for cervical dysplasia. According to the American Cancer Society, approximately 500,000 women are diagnosed with high-grade cervical dysplasia each year, with roughly 10,000 cases progressing to cervical cancer.

For numerous women afflicted with the common sexually transmitted disease known as human papillomavirus (HPV), the immune system can not prevent certain high-risk strains of the virus from causing cervical dysplasia, a common precursor to cervical cancer. "The expected widespread availability of two preventive vaccines may lower the incidence of HPV infection and reduce the risk of cervical cancer," said Enrigue Hernandez, The Abraham Roth Professor and Chair of the Department of Obstetrics and Gynecology at Temple University Hospital and School of Medicine. "However, for those women already infected with HPV, and those who will become infected, there are emerging non-surgical options in development."

HPV vaccines are expected to be a significant advance in women's healthcare, but they will not protect all women from cervical cancer. "Prophylactic vaccines will probably not help the more than 350,000 women in the U.S. already infected with HPV who have moderate to severe cervical dysplasia, a precancerous condition," explained Hernandez.

Amolimogene is an investigational immunotherapeutic from MGI PHARMA, Inc. that is currently being evaluated in a pivotal phase 2 clinical program in multiple centers in the U.S., including Philadelphia. "This product candidate is designed to enhance the body's immune response to cervical dysplasia, and is being developed to offer patients with cervical dysplasia and healthcare providers an option to surgical intervention," explained Hernandez. "Qualified participants must be 25 or younger, with an abnormal Pap te
'"/>

Contact: Vivica Aycox
vaycox@temple.edu
215-707-7790
Temple University Health System
30-Jan-2007


Page: 1 2

Related medicine news :

1. NIH awards $1 million to Temple University Hospital for neurological treatment studies
2. UPenn receives 2005 Templeton Research Lectures Grant
3. Indiana University Imaging Center receives $6M grant for kidney research
4. University hospitals wins multiple national IT awards for electronic patient data bank
5. RAND presents first Victor Fuchs Research Award to economists at Carnegie Mellon University
6. University research wins royal accolade
7. New Orleans levee report finished by panel including University of Texas at Austin engineer
8. Boston University School of Medicine faculty member receives honorary degree from alma mater
9. NY-Presbyterian Hospital/Columbia University Medical Center doctors present at 2007 AUA Meeting
10. Emory University researchers find persistent and severe asthma associated with obesity
11. Mid Sweden University leads development of digital color x-rays

Post Your Comments:
(Date:7/25/2014)... 25, 2014 Bedros Keuilian has been ... in the country, and is considered the industry’s leading ... on his coaching website, RenegadeMarketing.com, he explains why information ... a good personal trainer. , “I’ve been really privileged ... leaders in the fitness industry and I’ve helped many ...
(Date:7/25/2014)... for Medical Oncology (ESMO), the leading pan-European association ... the proposed EU General Data Protection Regulation [1] ... significant burden to both doctors and cancer patients. ... stipulates ,explicit and specific patient consent, meaning that ... time research is planned in order to consult ...
(Date:7/25/2014)... Seattle, Wa (PRWEB) July 25, 2014 ... More Pdf review recently updated by Vkool.com, ... teach people how to treat some common ...     External hemorrhoids and internal hemorrhoids , ... after pregnancy with hemorrhoids ,     Very ...
(Date:7/25/2014)... As the category creator and world leader in healthy ... transform and improve individual lives worldwide through its exclusive and ... a successful Austin, Texas based "Xocai Activ Drink" author, is ... July to promote the up and coming mxicorp.com/company/igc Eric Worre ... has been a leader in the Network Marketing Profession for ...
(Date:7/24/2014)... York, NY (PRWEB) July 25, 2014 ... innovator in health care quality, has been appointed senior ... effective July 21, 2014. In his new role, he ... initiatives. , Dr. Ting has successfully led quality initiatives ... levels. Nationally, he led teams for the Door-to-Balloon Alliance, ...
Breaking Medicine News(10 mins):Health News:Fitness Marketing Expert Bedros Keuilian’s New Post Shares Why People Still Need Personal Trainers in the Age of Google 2Health News:Fitness Marketing Expert Bedros Keuilian’s New Post Shares Why People Still Need Personal Trainers in the Age of Google 3Health News:Is Europe putting cancer research at risk? 2Health News:Hemorrhoid No More Pdf Review Exposes Jessica Wright's Guide For Treating Hemorrhoids – Vkool.com 2Health News:Hemorrhoid No More Pdf Review Exposes Jessica Wright's Guide For Treating Hemorrhoids – Vkool.com 3Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 2Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 3Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 4Health News:NewYork-Presbyterian Hospital Names New Senior Vice President for Quality and Patient Safety 2Health News:NewYork-Presbyterian Hospital Names New Senior Vice President for Quality and Patient Safety 3
(Date:7/25/2014)... 25, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... update and report second quarter 2014 financial results before ... 1, 2014. That same day, Arena will host a ... (5:30 a.m. Pacific Time). The conference ... callers and 914.495.8552 for international callers. Please specify to ...
(Date:7/24/2014)... , July 24, 2014  Parnell Pharmaceuticals Holdings ... that will be added to Parnell,s already extensive ... Pty Ltd, a biotechnology company. The compounds now ... shown promise in bone regeneration and dermal regeneration, ... the compounds for the veterinary market with the ...
(Date:7/24/2014)... Deutschland, und MARSEILLE , ... , Weltweite Exklusivlizenz der ... QIAGEN die Entwicklung von Tests auf SF3B1-Mutationen, ... Neuer Test weist Mutationen des ... (myelodysplastischen Syndromen) einen günstigen Krankheitsverlauf vermuten lassen  ...
Breaking Medicine Technology:Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
Cached News: